Naringenin and atherosclerosis: A review of literature

Current Pharmaceutical Biotechnology

Volumn 16, Issue 3, 2015, Pages 245-251

  Orhan, Ilkay E ^a   Nabavi, Seyed F ^b   Daglia, Maria ^c   Tenore, Gian C ^d   Mansouri, Kowsar ^b   Nabavi, Seyed M ^b  

^a GAZI UNIVERSITY   (Turkey)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atherosclerosis; Flavonoid; Grapefruit; Naringenin; Naringin; Oxidative stress

Indexed keywords

4 HYDROXYBENZOIC ACID; 4 HYDROXYPHENYLACETIC ACID; FLAVONOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NARINGENIN; OXYGENASE; PHLOROGLUCINOLCARBOXYLIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIOXIDANT; FLAVANONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CELL CYCLE ARREST; DRUG BIOAVAILABILITY; ENZYME INHIBITION; GLUCOSE TRANSPORT; HUMAN; LIPID PEROXIDATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MACROPHAGE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; FLAVANONES; FLAVONOIDS; HUMANS; MACROPHAGES; OXIDATIVE STRESS;

EID: 84938823225     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666141202110216     Document Type: Review

References (132)

1. Epstein, F.H.; Ross, R. Atherosclerosis-an inflammatory disease. New Eng. J. Med., 1999, 340(2), 115-126.
2. Zwaka, T.P.; Hombach, V.; Torzewski, J. C-reactive protein– mediated low density lipoprotein uptake by macrophages implications for atherosclerosis. Circulation, 2001, 103(9), 1194-1197.
3. Spady, D.; Woollett, L.; Dietschy, J. Regulation of plasma LDLcholesterol levels by dietary cholesterol and fatty acids. Ann. Rev. Nutrit., 1993, 13(1), 355-381.
4. Brouwer, I.A.; Wanders, A.J.; Katan, M.B. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans-a quantitative review. PLoS One, 2010, 5(3), e9434.
5. Newberry, E.P.; Kennedy, S.M.; Xie, Y.; Sternard, B.T.; Luo, J.; Davidson, N.O. Diet-induced obesity and hepatic steatosis in LFabp−/− mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Amer. J. Physiol.-Gastrointest. Liver Physiol., 2008, 294(1), G307-G314.
6. Newberry, E.P.; Xie, Y.; Kennedy, S.M.; Luo, J.; Davidson, N.O. Protection against Western diet–induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology, 2006, 44(5), 1191-1205.
7. Rahaman, S.O.; Lennon, D.J.; Febbraio, M.; Podrez, E.A.; Hazen, S.L.; Silverstein, R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metabolism, 2006, 4(3), 211-221.
8. Furuhashi, M.; Tuncman, G.; Görgün, C.Z.; Makowski, L.; Atsumi, G.; Vaillancourt, E.; Kono, K.; Babaev, V.R.; Fazio, S.; Linton, M.F. Treatment of diabetes and atherosclerosis by inhibiting fattyacid-binding protein aP2. Nature, 2007, 447(7147), 959-965.
9. Smith, S.C.; Allen, J.; Blair, S.N.; Bonow, R.O.; Brass, L.M.; Fonarow, G.C.; Grundy, S.M.; Hiratzka, L.; Jones, D.; Krumholz, H.M., AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update Endorsed by the National Heart, Lung, and Blood Institute. J. Amer. Coll. Cardiol., 2006, 47(10), 2130-2139.
10. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347), 317-325.
11. Conlan, M.G.; Folsom, A.R.; Finch, A.; Davis, C.; Sorlie, P.; Marcucci, G.; Wu, K. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thrombos. Haemostasis, 1993, 70(3), 380-385.
12. Glowinska, B.; Urban, M.; Koput, A.; Galar, M. New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Atherosclerosis, 2003, 167(2), 275-286.
13. Nieto, F.J.; Alonso, J.; Chambless, L.E.; Zhong, M.; Ceraso, M.; Romm, F.J.; Cooper, L.; Folsom, A.R.; Szklo, M. Population awareness and control of hypertension and hypercholesterolemia: The Atherosclerosis Risk in Communities Study. Archiv. Internal Med., 1995, 155(7), 677-684.
14. Howard, G.; Wagenknecht, L.E.; Burke, G.L.; Diez-Roux, A.; Evans, G.W.; McGovern, P.; Nieto, F.J.; Tell, G.S. Investigators, A. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Jama, 1998, 279(2), 119-124.
15. Stocker, R.; Keaney JrJ.F. Role of oxidative modifications in atherosclerosis. Physiologic. Rev., 2004, 84(4), 1381-1478.
16. Ross, R.; Glomset, J.; Harker, L. Response to injury and atherogenesis. Amer. J. Pathol., 1977, 86(3), 675.
17. Williams, K.J.; Tabas, I. The response-to-retention hypothesis of early atherogenesis. Arteriosclerosis, Thrombos, Vascular Biol., 1995, 15(5), 551-561.
18. Benditt, E.P.; Benditt, J.M. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc. Natl. Acad. Sci., 1973, 70(6), 1753-1756.
19. Napoli, C.; D'armiento, F.; Mancini, F.; Postiglione, A.; Witztum, J.; Palumbo, G.; Palinski, W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Investigat., 1997, 100(11), 2680.
20. Sparrow, C.P.; Parthasarathy, S.; Steinberg, D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J. Biologic. Chem., 1989, 264(5), 2599-2604.
21. Taniyama, Y.; Griendling, K.K. Reactive oxygen species in the vasculature molecular and cellular mechanisms. Hypertension, 2003, 42(6), 1075-1081.
22. Irani, K. Oxidant signaling in vascular cell growth, death, and survival a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circulat. Res., 2000, 87(3), 179-183.
23. Lönn, M.E.; Dennis, J.M.; Stocker, R. Actions of “antioxidants” in the protection against atherosclerosis. Free Radical Biol. Med., 2012, 53(4), 863-884.
24. Alinezhad, H.; Azimi, R.; Zare, M.; Ebrahimzadeh, M.A.; Eslami, S.; Nabavi, S.F.; Nabavi, S.M. Antioxidant and antihemolytic activities of ethanolic extract of flowers, leaves, and stems of Hyssopus officinalis L. Var. angustifolius. Int. J. Food Properties, 2013, 16(5), 1169-1178.
25. Nabavi, S.F.; Nabavi, S.M.; Habtemariam, S.; Moghaddam, A.H.; Sureda, A.; Jafari, M.; Latifi, A.M. Hepatoprotective effect of gallic acid isolated from Peltiphyllum peltatum against sodium fluoride- induced oxidative stress. Industrial Crops Products, 2013, 44, 50-55.
26. Kahl, R.; Kappus, H. Toxicology of the synthetic antioxidants BHA and BHT in comparison with the natural antioxidant vitamin E. Zeitschrift fur Lebensmittel-untersuchung und-forschung, 1993, 196(4), 329-338.
27. Nabavi, S.F.; Nabavi, S.M.; Ebrahimzadeh, M.A.; Eslami, B.; Jafari, N. In vitro antioxidant and antihemolytic activities of hydroalcoholic extracts of Allium scabriscapum Boiss. & Ky. Aerial Parts and Bulbs. Int. J. Food Properties, 2013, 16(4), 713-722.
28. Nabavi, S.F.; Daglia, M.; Moghaddam, A.H.; Habtemariam, S.; Nabavi, S.M. Curcumin and Liver disease: From chemistry to medicine. Comprehensive Rev. Food Sci. Food Safety, 2014, 13(1), 62-77.
29. Tachjian, A.; Maria, V.; Jahangir, A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J. Amer. Coll. Cardiol., 2010, 55(6), 515-525.
30. Mashour, N.H.; Lin, G.I.; Frishman, W.H. Herbal medicine for the treatment of cardiovascular disease: Clinical considerations. Archiv. Internal Med., 1998, 158(20), 2225-2234.
31. Shiao, M.-S.; Chiu, J.-J.; Chang, B.-W.; Wang, J.; Jen, W.-P.; Wu, Y.-J.; Chen, Y.-L. In search of antioxidants and anti-atherosclerotic agents from herbal medicines. Biofactors, 2008, 34(2), 147-157.
32. Nabavi, S.M.; Daglia, M.; Moghaddam, A.H.; Nabavi, S.F.; Curti, V. Tea consumption and risk of ischemic stroke: A Brief Review of the Literature. Curr. Pharmaceut. Biotechnol., 2014, 15(4), 298-303.
33. Joshipura, K.J.; Hu, F.B.; Manson, J.E.; Stampfer, M.J.; Rimm, E.B.; Speizer, F.E.; Colditz, G.; Ascherio, A.; Rosner, B.; Spiegelman, D. The effect of fruit and vegetable intake on risk for coronary heart disease. Annals Internal Med., 2001, 134(12), 1106-1114.
34. Dauchet, L.; Amouyel, P.; Hercberg, S.; Dallongeville, J. Fruit and vegetable consumption and risk of coronary heart disease: A metaanalysis of cohort studies. J. Nutrit., 2006, 136(10), 2588-2593.
35. Joshipura, K.J.; Ascherio, A.; Manson, J.E.; Stampfer, M.J.; Rimm, E.B.; Speizer, F.E.; Hennekens, C.H.; Spiegelman, D.; Willett, W.C. Fruit and vegetable intake in relation to risk of ischemic stroke. Jama, 1999, 282(13), 1233-1239.
36. Nabavi, S.F.; Nabavi, S.M.; Mirzaei, M.; Moghaddam, A.H. Protective effect of quercetin against sodium fluoride induced oxidative stress in rat’s heart. Food Funct., 2012, 3(4), 437-441.
37. Nabavi, S.F.; Nabavi, S.M.; N Setzer, W.; Nabavi, S.A.; Nabavi, S.A.; Ebrahimzadeh, M.A. Antioxidant and antihemolytic activity of lipid-soluble bioactive substances in avocado fruits. Fruits, 2013, 68(03), 185-193.
38. Nabavi, S.F.; Nabavi, S.M.; Moghaddam, A.H.; Naqinezhad, A.; Bigdellou, R.; Mohammadzadeh, S. Protective effects of Allium paradoxum against gentamicin-induced nephrotoxicity in mice. Food Funct., 2012, 3(1), 28-29.
39. Curti, V.; Capelli, E.; Boschi, F.; Nabavi, S.F.; Bongiorno, A.I.; Habtemariam, S.; Nabavi, S.M.; Daglia, M. Modulation of human miR-17–3p expression by methyl 3‐O‐methyl gallate as explanation of its in vivo protective activities. Molecular Nutrit. Food Res., 2014, 58(9), 1776-1784.
40. Nabavi, S.F.; Nabavi, S.M.; Ebrahimzadeh, M.A.; Jafari, N.; Yazdanpanah, S. Biological activities of freshwater algae, spirogyra singularis nordstedt. J. Aquatic Food Product Technol., 2013, 22(1), 58-65.
41. Nabavi, S.M.; Nabavi, S.F.; Eslami, S.; Moghaddam, A.H. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem., 2012, 132(2), 931-935.
42. Heo, H.J.; Kim, D.-O.; Shin, S.C.; Kim, M.J.; Kim, B.G.; Shin, D.-H. Effect of antioxidant flavanone, naringenin, from Citrus junos on neuroprotection. J. Agricult. Food Chem., 2004, 52(6), 1520-1525.
43. Vafeiadou, K.; Vauzour, D.; Lee, H.Y.; Rodriguez-Mateos, A.; Williams, R.J.; Spencer, J.P., The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Archiv. Biochem. Biophys., 2009, 484(1), 100-109.
44. Wilcox, L.J.; Borradaile, N.M.; Huff, M.W. Antiatherogenic properties of naringenin, a citrus flavonoid. Cardiovascular Drug Rev., 1999, 17(2), 160-178.
45. Jourdan, P.S.; McIntosh, C.A.; Mansell, R.L. Naringin levels in Citrus tissues II. Quantitative distribution of naringin in Citrus paradisi Macfad. Plant Physiol., 1985, 77(4), 903-908.
46. Pulley, G.N. Solubility of naringin in water. Industrial Engineer. Chem. Analyt. Ed., 1936, 8(5), 360-360.
47. Rouseff, R.L.; Martin, S.F.; Youtsey, C.O. Quantitative survey of narirutin, naringin, hesperidin, and neohesperidin in citrus. J. Agricult. Food Chem., 1987, 35(6), 1027-1030.
48. Okwu, D.E. Citrus fruits: A rich source of phytochemicals and their roles in human health. Int. J. Chemical Sci., 2008, 6(2), 451-471.
49. Yamamoto, T.; Yoshimura, M.; Yamaguchi, F.; Kouchi, T.; Tsuji, R.; Saito, M.; Obata, A.; Kikuchi, M. Anti-allergic activity of naringenin chalcone from a tomato skin extract. Biosci., Biotechnol. Biochem., 2004, 68(8), 1706-1711.
50. Chang, C.-C.; Yang, M.H.; Wen, H.M.; Chern, J.C. Estimation of total flavonoid content in propolis by two complementary colorimetric methods. J. Food Drug Analys., 2002, 10(3), 178-182.
51. Rice-Evans, C. Flavonoid antioxidants. Curr. Medicin. Chem., 2001, 8(7), 797-807.
52. Cao, G.; Sofic, E.; Prior, R.L. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radical Biol. Med., 1997, 22(5), 749-760.
53. Vinson, J.A.; Liang, X.; Proch, J.; Hontz, B.A.; Dancel, J.; Sandone, N. In Flavonoids in Cell Function; Springer, 2002, pp 113-122.
54. Brett, G.M.; Hollands, W.; Needs, P.W.; Teucher, B.; R Dainty, J.; Davis, B.D.; Brodbelt, J.S.; Kroon, P.A. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Brit. J. Nutrit., 2009, 101(05), 664-675.
55. Kanaze, F.; Bounartzi, M.; Georgarakis, M.; Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Europ. J. Clin. Nutrit., 2006, 61(4), 472-477.
56. Manach, C.; Scalbert, A.; Morand, C.; Rémésy, C.; Jiménez, L., Polyphenols: food sources and bioavailability. Amer. J. Clin. Nutrit., 2004, 79(5), 727-747.
57. Erlund, I., Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutrit. Res., 2004, 24(10), 851-874.
58. Day, A.J.; DuPont, M.S.; Ridley, S.; Rhodes, M.; Rhodes, M.J.; Morgan, M.R.; Williamson, G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β - glucosidase activity. FEBS Lett., 1998, 436(1), 71-75.
59. Fuhr, U.; Kummert, A.L., The fate of naringin in humans: A key to grapefruit juice-drug interactions? Clin. Pharmacol. Therapeut., 1995, 58(4), 365-373.
60. Kim, D.-H.; Jung, E.-A.; Sohng, I.-S.; Han, J.-A.; Kim, T.-H.; Han, M.J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Archiv. Pharmacal Res., 1998, 21(1), 17-23.
61. Rechner, A.R.; Smith, M.A.; Kuhnle, G.; Gibson, G.R.; Debnam, E.S.; Srai, S.K.S.; Moore, K.P.; Rice-Evans, C.A. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radical Biol. Med., 2004, 36(2), 212-225.
62. Griffiths, L.; Smith, G., Metabolism of apigenin and related compounds in the rat. Metabolite formation in vivo and by the intestinal microflora in vitro. Biochem. J., 1972, 128, 901-911.
63. Spencer, J.P.; Abd El Mohsen, M.M.; Rice-Evans, C. Cellular uptake and metabolism of flavonoids and their metabolites: Implications for their bioactivity. Archiv. Biochem. Biophys., 2004, 423(1), 148-161.
64. Silberberg, M.; Gil-Izquierdo, A.; Combaret, L.; Remesy, C.; Scalbert, A.; Morand, C., Flavanone metabolism in healthy and tumorbearing rats. Biomed. Pharmacotherap., 2006, 60(9), 529-535.
65. Meng, S.; Wu, B.; Singh, R.; Yin, T.; Morrow, J.K.; Zhang, S.; Hu, M., SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Molecul. Pharmaceut., 2012, 9(4), 862-873.
66. Fuhr, U.; Müller-Peltzer, H.; Kern, R.; Lopez-Rojas, P.; Jünemann, M.; Harder, S.; Staib, H.A., Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Europ. J. Clin. Pharmacol., 2002, 58(1), 45-53.
67. Felgines, C.; Texier, O.; Morand, C.; Manach, C.; Scalbert, A.; Régerat, F.; Rémésy, C., Bioavailability of the flavanone naringenin and its glycosides in rats. Amer. J. Physiol.-Gastrointestinal Liver Physiol., 2000, 279(6), G1148-G1154.
68. Tsai, T.-H., Determination of naringin in rat blood, brain, liver, and bile using microdialysis and its interaction with cyclosporin a, a pglycoprotein modulator. J. Agricult. Food Chem., 2002, 50(23), 6669-6674.
69. Wang, M.-J.; Chao, P.-D.L.; Hou, Y.-C.; Hsiu, S.-L.; Wen, K.-C.; Tsai, S.-Y., Pharmacokinetics and conjugation metabolism of naringin and naringenin in rats after single dose and multiple dose administrations. 2006, 14(3), 247-253.
70. Nielsen, S.; Breinholt, V.; Justesen, U.; Cornett, C.; Dragsted, L. In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica, 1998, 28(4), 389-401.
71. Erlund, I.; Meririnne, E.; Alfthan, G.; Aro, A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J. Nutrition, 2001, 131(2), 235-241.
72. Booth, A.N.; Jones, F.T.; DeEds, F. Metabolic and glucosuria studies on naringin and phloridzin. J. Biologic. Chem., 1958, 233(2), 280-282.
73. Ameer, B.; Weintraub, R.A.; Johnson, J.V.; Yost, R.A.; Rouseff, R.L. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Therapeut. 1996, 60(1), 34-40.
74. Maron, D.J. Flavonoids for reduction of atherosclerotic risk. Curr. Atherosclerosis Reports, 2004, 6(1), 73-78.
75. Riemersma, R.; Rice-Evans, C.; Tyrrell, R.; Clifford, M.; Lean, M. Tea flavonoids and cardiovascular health. Qjm, 2001, 94(5), 277-282.
76. Landberg, R.; Naidoo, N.; van Dam, R.M. Diet and endothelial function: from individual components to dietary patterns. Curr. Opin. Lipidol., 2012, 23(2), 147-155.
77. Khurana, S.; Piche, M.; Hollingsworth, A.; Venkataraman, K.; Tai, T. Oxidative stress and cardiovascular health: therapeutic potential of polyphenols 1. Canad. J. Physiol. Pharmacol., 2013, 91(3), 198-212.
78. A Islam, M.; W Schmidt, R.; Gunaseelan, S.; Sanchez, A. An update on the cardiovascular effects of quercetin, a plant flavonoid. Curr. Nutrit. Food Sci., 2014, 10(1), 36-48.
79. Jeon, S.-M.; Bok, S.-H.; Jang, M.-K.; Lee, M.-K.; Nam, K.-T.; Park, Y.B.; Rhee, S.-J.; Choi, M.-S. Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. Life Sci., 2001, 69(24), 2855-2866.
80. Tripoli, E.; Guardia, M.L.; Giammanco, S.; Majo, D.D.; Giammanco, M. Citrus flavonoids: Molecular structure, biological activity and nutritional properties: A review. Food Chem., 2007, 104(2), 466-479.
81. Yen, J.H.; Weng, C.Y.; Li, S.; Lo, Y.H.; Pan, M.H.; Fu, S.H.; Ho, C.T.; Wu, M.J. Citrus flavonoid 5‐demethylnobiletin suppresses scavenger receptor expression in THP-1 cells and alters lipid homeostasis in HepG2 liver cells. Mol. Nutrit. Food Res., 2011, 55(5), 733-748.
82. Mulvihill, E.E.; Huff, M.W. Protection from metabolic dysregulation, obesity, and atherosclerosis by citrus flavonoids: Activation of hepatic PGC1α-mediated fatty acid oxidation. PPAR Res., 2012, 2012.
83. Assini, J.M.; Mulvihill, E.E.; Huff, M.W. Citrus flavonoids and lipid metabolism. Curr. Opin. Lipidology, 2013, 24(1), 34-40.
84. Chan, T.; Galati, G.; O’Brien, P.J. Oxygen activation during peroxidase catalysed metabolism of flavones or flavanones. Chemicobiological Interactions, 1999, 122(1), 15-25.
85. Santos, K.; Oliveira, T.; Nagem, T.; Oliveira, M. Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations. Pharmacol. Res., 1999, 40(6), 493-496.
86. Robinson, J.; L'herminier, M.; Claudet, H. The effect of naringenin on the intestinal and renal transport of organic solutes. Naunyn-Schmiedeberg's Archives Pharmacol., 1979, 307(1), 79-89.
87. Mortensen, A.; Breinholt, V.; Dalsgaard, T.; Frandsen, H.; Lauridsen, S.T.; Laigaard, J.; Ottesen, B.; Larsen, J.-J. 17β-Estradiol but not the phytoestrogen naringenin attenuates aortic cholesterol accumulation in WHHL rabbits. J. Lipid Res., 2001, 42(5), 834-843.
88. Stevens, J.F.; Miranda, C.L.; Frei, B.; Buhler, D.R. Inhibition of peroxynitrite-mediated LDL oxidation by prenylated flavonoids: the α, β-unsaturated keto functionality of 2'-hydroxychalcones as a novel antioxidant pharmacophore. Chem. Res. Toxicol., 2003, 16(10), 1277-1286.
89. Firuzi, O.; Mladenka, P.; Petrucci, R.; Marrosu, G.; Saso, L. Hypochlorite scavenging activity of flavonoids. J. Pharma. Pharmacol., 2004, 56(6), 801-807.
90. Park, J.B. Flavonoids are potential inhibitors of glucose uptake in U937 cells. Biochem. Biophys. Res. Commun., 1999, 260(2), 568-574.
91. Lotito, S.B.; Frei, B. Dietary flavonoids attenuate tumor necrosis factor α-induced adhesion molecule expression in human aortic endothelial cells structure-function relationships and activity after first pass metabolism. J. Bio. Chem., 2006, 281(48), 37102-37110.
92. Owens, E.O.; Toborek, M.; Hennig, B. Flavonoids protect against intercellular adhesion molecule-1 induction by benzo [a] pyrene. Bullet. Environ. Contamin. Toxicol., 2009, 83(1), 4-7.
93. Lee, J.-J.; Yi, H.; Kim, I.-S.; Kim, Y.; Nhiem, N.X.; Kim, Y.H.; Myung, C.-S., (2 S)-Naringenin from Typha angustata inhibits vascular smooth muscle cell proliferation via a G arrest. J. Ethnopharmacol., 2012, 139(3), 873-878.
94. Chen, S.; Ding, Y.; Tao, W.; Zhang, W.; Liang, T.; Liu, C. Naringenin inhibits TNF-α induced VSMC proliferation and migration via induction of HO-1. Food Chem. Toxicol., 2012, 50(9), 3025-3031.
95. Chanet, A.; Milenkovic, D.; Claude, S.; Maier, J.A.; Kamran Khan, M.; Rakotomanomana, N.; Shinkaruk, S.; Bérard, A.M.; Bennetau-Pelissero, C.; Mazur, A. Flavanone metabolites decrease monocyte adhesion to TNF-α-activated endothelial cells by modulating expression of atherosclerosis-related genes. Brit. J. Nutrition, 2013, 110(04), 587-598.
96. Ribeiro, D.; Freitas, M.; Tomé, S.M.; Silva, A.; Porto, G.; Cabrita, E.J.; Marques, M.M.B.; Fernandes, E. Inhibition of LOX by flavonoids: a structure–activity relationship study. Eur. J. Medic. Chem., 2014, 72, 137-145.
97. Assini, J.M.; Mulvihill, E.E.; Sutherland, B.G.; Telford, D.E.; Sawyez, C.G.; Felder, S.L.; Chhoker, S.; Edwards, J.Y.; Gros, R.; Huff, M.W. Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr−/− mice. J. Lipid Res., 2013, 54(3), 711-724.
98. Lahera, V.; Goicoechea, M.; Garcia de Vinuesa, S.; Miana, M.; Heras, N.D.L.; Cachofeiro, V.; Luno, J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr. Medic. Chem., 2007, 14(2), 243-248.
99. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105(9), 1135-1143.
100. Weber, C.; Zernecke, A.; Libby, P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat. Rev. Immunol., 2008, 8(10), 802-815.
101. Tedgui, A.; Mallat, Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol. Rev., 2006, 86(2), 515-581.
102. De Maat, M.; Bladbjerg, E.; Drivsholm, T.; Borch-Johnsen, K.; Møller, L.; Jespersen, J. Inflammation, thrombosis and atherosclerosis: Results of the Glostrup study. J. Thromb. Haemostas., 2003, 1(5), 950-957.
103. Libby, P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am. J. Cardio., 2000, 86(8), 3-8.
104. Charo, I.F.; Taub, R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat. Rev. Drug Discov., 2011, 10(5), 365-376.
105. Jiang, C.; Ting, A.T.; Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391(6662), 82-86.
106. Su, C.G.; Wen, X.; Bailey, S.T.; Jiang, W.; Rangwala, S.M.; Keilbaugh, S.A.; Flanigan, A.; Murthy, S.; Lazar, M.A.; Wu, G.D. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Investig., 1999, 104(104 (4)), 383-389.
107. Murphy, G.J.; Holder, J.C. PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol. Sci., 2000, 21(12), 469-474.
108. Daynes, R.A.; Jones, D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol., 2002, 2(10), 748-759.
109. Mishra, A.; Chaudhary, A.; Sethi, S. Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-dependent pathway. Arterioscler. Thromb. Vascu. Bio., 2004, 24(9), 1621-1627.
110. Diep, Q.N.; Amiri, F.; Touyz, R.M.; Cohn, J.S.; Endemann, D.; Neves, M.F.; Schiffrin, E.L. PPARα activator effects on ang II– induced vascular oxidative stress and inflammation. Hyperten., 2002, 40(6), 866-871.
111. Rival, Y.; Benéteau, N.; Taillandier, T.; Pezet, M.; Dupont-Passelaigue, E.; Patoiseau, J.-F.; Junquéro, D.; Colpaert, F.C.; Delhon, A. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol., 2002, 435(2), 143-151.
112. Zandbergen, F.; Plutzky, J. PPARα in atherosclerosis and inflammation. Biochim. Biophys. Acta (BBA)-Mol. Cell Bio. Lipids, 2007, 1771(8), 972-982.
113. Duval, C.; Chinetti, G.; Trottein, F.; Fruchart, J.-C.; Staels, B. The role of PPARs in atherosclerosis. Trends Mol. Med., 2002, 8(9), 422-430.
114. Takata, Y.; Liu, J.; Yin, F.; Collins, A.R.; Lyon, C.J.; Lee, C.-H.; Atkins, A.R.; Downes, M.; Barish, G.D.; Evans, R.M. PPAR δ-mediated antiinflammatory mechanisms inhibit angiotensin IIaccelerated atherosclerosis. Proc. Nat. Acad. Sci., 2008, 105(11), 4277-4282.
115. Chinetti, G.; Lestavel, S.; Bocher, V.; Remaley, A.T.; Neve, B.; Torra, I.P.; Teissier, E.; Minnich, A.; Jaye, M.; Duverger, N. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med., 2001, 7(1), 53-58.
116. Guerre-Millo, M.; Gervois, P.; Raspé, E.; Madsen, L.; Poulain, P.; Derudas, B.; Herbert, J.-M.; Winegar, D.A.; Willson, T.M.; Fruchart, J.-C. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem., 2000, 275(22), 16638-16642.
117. Nofer, J.-R.; Kehrel, B.; Fobker, M.; Levkau, B.; Assmann, G.; Eckardstein, A.V. HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis, 2002, 161(1), 1-16.
118. O’Connell, B.J.; Genest, J. High-density lipoproteins and endothelial function. Circulation, 2001, 104(16), 1978-1983.
119. Barter, P.J.; Nicholls, S.; Rye, K.-A.; Anantharamaiah, G.; Navab, M.; Fogelman, A.M. Antiinflammatory properties of HDL. Circulation Res., 2004, 95, (8), 764-772.
120. Assmann, G.; Gotto, A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation, 2004, 109(23 Suppl 1), III-8-III-14.
121. Levine, G.N.; Frei, B.; Koulouris, S.N.; Gerhard, M.D.; Keaney, J.F.; Vita, J.A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation, 1996, 93(6), 1107-1113.
122. Kushi, L.H.; Folsom, A.R.; Prineas, R.J.; Mink, P.J.; Wu, Y.; Bostick, R.M. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. New Eng. J. Med., 1996, 334(18), 1156-1162.
123. Hertog, M.G.; Feskens, E.J.; Kromhout, D.; Hertog, M.; Hollman, P.; Hertog, M.; Katan, M. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet, 1993, 342(8878), 1007-1011.
124. Valgimigli, M.; Merli, E.; Malagutti, P.; Soukhomovskaia, O.; Cicchitelli, G.; Macrı̀, G.; Ferrari, R. Endothelial dysfunction in acute and chronic coronary syndromes: Evidence for a pathogenetic role of oxidative stress. Archives Biochem. Biophys., 2003, 420(2), 255-261.
125. Channon, K.M. Oxidative stress and coronary plaque stability. Arterioscler. Thromb. Vascul. Bio., 2002, 22(11), 1751-1752.
126. Pueyo, M.E.; Gonzalez, W.; Nicoletti, A.; Savoie, F.; Arnal, J.-F.; Michel, J.-B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler. Thrombo. Vascul. Bio., 2000, 20(3), 645-651.
127. Minuz, P.; Patrignani, P.; Gaino, S.; Degan, M.; Menapace, L.; Tommasoli, R.; Seta, F.; Capone, M.L.; Tacconelli, S.; Palatresi, S. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation, 2002, 106(22), 2800-2805.
128. Goldwasser, J.; Cohen, P.Y.; Yang, E.; Balaguer, P.; Yarmush, M.L.; Nahmias, Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: Role of PPARα, PPARγ and LXRα. PLoS One, 2010, 5(8), e12399.
129. Cho, K.W.; Kim, Y.O.; Andrade, J.E.; Burgess, J.R.; Kim, Y.-C. Dietary naringenin increases hepatic peroxisome proliferators–activated receptor α protein expression and decreases plasma triglyceride and adiposity in rats. Eur. J. Nutrition, 2011, 50(2), 81-88.
130. Kurowska, E.M.; Spence, J.D.; Jordan, J.; Wetmore, S.; Freeman, D.J.; Piché, L.A.; Serratore, P. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am. J. Clin. Nutrition, 2000, 72(5), 1095-1100.
131. Zern, T.L.; Wood, R.J.; Greene, C.; West, K.L.; Liu, Y.; Aggarwal, D.; Shachter, N.S.; Fernandez, M.L. Grape polyphenols exert a cardioprotective effect in pre-and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J. Nutrition, 2005, 135(8), 1911-1917.
132. Gaggeri, R.; Rossi, D.; Daglia, M.; Leoni, F.; Avanzini, M.A.; Mantelli, M.; Juza, M.; Collina, S. An ecofriendly enantioselective access to (R)-Naringenin as inhibitor of proinflammatory cytokines release. Chem. Biodivers., 2013, 10(8), 1531-1538.